- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02055482
Long-term Pre-dialysis Extension in Europe and Asia Pacific (DIALOGUE 3)
A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Darbepoetin Alfa Comparator in the Long Term Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease in Europe and Asia Pacific
Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.
The purpose of this extension study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.
The extension study will enroll up to 240 patients at multiple locations in Europe, Asia and Australia. Patients who participated in Studies 15141 or 15261 may be eligible to take part in the extension study. The study consists of the Haemoglobin (Hb) Stabilisation Phase and the Main Phase. The Hb Stabilisation Phase involves up to 10 study visits scheduled over 16 weeks. The Main Phase will last for at least 6 months and up to a maximum of 36 months, with visits every 4 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.
The study will be conducted at 5 hospitals in the UK. Bayer HealthCare AG is funding this research. This study will include subjects who either completed the treatment period in their respective Phase 2 parent study (i.e., Study 15141 or Study 15261) or experienced a stopping event in the fixed dose parent study (Study 15141). As Study 15141 is a double-blind study, subjects will be unblinded as per the Study 15141 protocol prior to entry into the extension study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Reservoir, Australia, 3073
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
-
-
Victoria
-
Melbourne, Victoria, Australia, 3052
-
-
-
-
-
Burgas, Bulgaria, 8000
-
Dobrich, Bulgaria, 9300
-
Gabrovo, Bulgaria, 5300
-
Karlovo, Bulgaria, 4300
-
Lovech, Bulgaria, 5500
-
Montana, Bulgaria, 3400
-
Pazardjik, Bulgaria, 4400
-
Sofia, Bulgaria, 1431
-
Sofia, Bulgaria, 1527
-
Sofia, Bulgaria, 1309
-
Sofia, Bulgaria, 1872
-
Stara Zagora, Bulgaria, 6000
-
Veliko Tarnovo, Bulgaria, 5000
-
-
-
-
-
Brest Cedex, France, 29609
-
Grenoble Cedex 9, France, 38043
-
Limoges Cedex1, France, 87042
-
Pierre Benite Cedex, France, 69495
-
Valenciennes, France, 59300
-
-
-
-
-
Berlin, Germany, 12053
-
Wuppertal, Germany, 42283
-
-
Baden-Württemberg
-
Pirmasens, Baden-Württemberg, Germany, 66953
-
Villingen-Schwenningen, Baden-Württemberg, Germany, 78052
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53127
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40210
-
-
Sachsen-Anhalt
-
Halle (Saale), Sachsen-Anhalt, Germany, 06097
-
-
-
-
-
Baja, Hungary, 6500
-
Budapest, Hungary, 1036
-
Debrecen, Hungary, 4032
-
Esztergom, Hungary, 2500
-
Kaposvar, Hungary, 7400
-
Pecs, Hungary, 7624
-
Szigetvar, Hungary, 7900
-
-
-
-
-
Ashkelon, Israel, 7827804
-
Hadera, Israel, 3810101
-
Jerusalem, Israel, 9112001
-
Kfar Saba, Israel, 4428164
-
Nahariya, Israel, 2210001
-
-
-
-
Abruzzo
-
Chieti, Abruzzo, Italy, 66013
-
-
Campania
-
Napoli, Campania, Italy, 80138
-
-
Emilia-Romagna
-
Modena, Emilia-Romagna, Italy, 41100
-
-
Lombardia
-
Brescia, Lombardia, Italy, 25123
-
Cremona, Lombardia, Italy, 26100
-
Lecco, Lombardia, Italy, 23900
-
Milano, Lombardia, Italy, 20132
-
Milano, Lombardia, Italy, 20162
-
Pavia, Lombardia, Italy, 27100
-
-
Toscana
-
Livorno, Toscana, Italy, 57023
-
-
-
-
-
Chiba, Japan, 260-8712
-
Fukuoka, Japan, 810-8563
-
Nagano, Japan, 388-8004
-
Nara, Japan, 631-0846
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan, 802-8555
-
Okawa, Fukuoka, Japan, 831-0016
-
-
Hokkaido
-
Muroran, Hokkaido, Japan, 050-0083
-
-
Ishikawa
-
Hakusan, Ishikawa, Japan, 924-8588
-
-
Iwate
-
Morioka, Iwate, Japan, 020-0066
-
-
Kanagawa
-
Fujisawa, Kanagawa, Japan, 251-8550
-
Kamakura, Kanagawa, Japan, 247-8533
-
-
Mie
-
Kuwana, Mie, Japan, 511-0061
-
-
-
-
-
Seoul, Korea, Republic of, 156-755
-
Seoul, Korea, Republic of, 03080
-
Seoul, Korea, Republic of, 156-707
-
-
Gyeonggido
-
Bucheon-si, Gyeonggido, Korea, Republic of, 420-767
-
-
-
-
-
Bialystok, Poland, 15-540
-
Poznan, Poland, 61-858
-
Radom, Poland, 26-610
-
Szczecin, Poland, 70-111
-
Zyrardow, Poland, 96-300
-
-
-
-
-
Brasov, Romania, 500152
-
Bucharest, Romania, 010731
-
Bucharest, Romania, 020475
-
Bucharest, Romania, 050098
-
Constanta, Romania, 900591
-
Oradea, Romania, 410469
-
Targu-Mures, Romania, 540103
-
-
-
-
-
Alicante, Spain, 03010
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08035
-
Córdoba, Spain, 14004
-
Madrid, Spain, 28041
-
Madrid, Spain, 28007
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spain, 15706
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
-
-
Madrid
-
San Sebastián de los Reyes, Madrid, Spain, 28702
-
-
-
-
-
Ankara, Turkey, 06100
- Ankara Univ. Medical Faculty
-
Ankara, Turkey, 06490
- Baskent University Medical Faculty
-
Izmir, Turkey, 03540
- Sifa University Medical Faculty
-
-
-
-
-
Chorley, United Kingdom, PR7 7NA
-
Glasgow, United Kingdom, G20 OSP
-
Liverpool, United Kingdom, L7 8XP
-
Liverpool, United Kingdom, L22 0LG
-
London, United Kingdom
-
London, United Kingdom, SE5 9RS
-
Manchester, United Kingdom, M15 6SX
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG2 0TG
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
-
-
Dundee City
-
Dundee, Dundee City, United Kingdom, DD1 9SY
-
-
East Sussex
-
Brighton, East Sussex, United Kingdom, BN2 5BE
-
-
Manchester
-
Salford, Manchester, United Kingdom, M5 5AP
-
-
Northumberland
-
Hexham, Northumberland, United Kingdom, NE46 1QJ
-
-
South Yorkshire
-
Doncaster, South Yorkshire, United Kingdom, DN2 5LT
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, WF3 4PX
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men who agree to use adequate contraception when sexually active or women without childbearing potential
- Not on dialysis at study entry
- Serum ferritin levels ≥ 100 μg/L and < 1000 μg/L or transferrin saturation ≥ 20%
- Inclusion criteria for inclusion into the Hb Stabilization (HbS) Phase: Requires Hb stabilization (at 10.0 to 12..0g/dL for a minimum of 4 weeks) as follows: Received BAY 85-3934 and reached a stopping event in Study 15141 or received placebo and reached a stopping event in Study 15141 or completed 16 weeks of treatment with BAY 85-3934 in Study 15141or 15261 but had mean Hb during the evaluation period outside the target range of 10.0 to 12.0 g/dL, or Completed 16 weeks of treatment with placebo in Study 15141 and was re-assessed at 4 weeks after end of study as eligible for Study 15653 (this study)
- Inclusion criteria for inclusion into the Main Phase: Mean Hb concentration of 10.0 to 12.0 g/dL who completed 16 weeks of treatment (BAY85-3934 arm) in Study 15141, or completed 16 weeks of treatment (BAY-3934 or darbepoetin arm)in study 15261 without a dose suspension lasting > 6 consecutive weeks, or mean Hb concentration of 10.0 to 12.0g/dL during the HbS phase of Study 15653 for a minimum of 4 weeks after visit 3.
Exclusion Criteria:
- A scheduled kidney transplant or any other organ transplant within the next 6 months (being on a waiting list does not exclude the subject)
- Red blood cell (RBC) containing transfusion within the 8 weeks before baseline
- Phosphodiesterase type 5 (PDE5) inhibitor (e.g., sildenafil, vardenafil, tadalafil) or nitrates
- Sustained, poorly controlled arterial hypertension or hypotension at baseline, defined as blood pressure ≥ 180/110 mmHg or systolic blood pressure < 95 mmHg, respectively
- Severe rhythm or conduction disorders (e.g., heart rate [HR] < 50 or > 110 bpm, atrial flutter, prolonged QT > 500 msec, second or third degree atrioventricular [AV] block), if not reacted with a pace marker)
- New York Heart Association Class III or IV congestive heart failure
- Severe hepatic insufficiency (defined as alanine aminotransferase [ALT], aspartate aminotransferase [AST]>3x the upper limit of normal [ULN], total bilirubin > 2 mg/dL, or Child Pugh B or C) or active hepatitis, in the investigator's opinion
- An ongoing serious adverse event (SAE) from Study 15141 or Study 15261 that is assessed as related to study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAY85-3934
|
BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL.
Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD.
Treatment will be for minimum of 6 months to up to a maximum of 36 months.
|
Active Comparator: Darbepoetin
|
Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection.
Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in local laboratory hemoglobin level from baseline
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Number of participants with serious adverse events (SAEs) and adjucated adverse events as a measure of safety and tolerability
Time Frame: Up to 36 months
|
Up to 36 months
|
Number of participants with liver function-related AEs including abnormal liver function tests and any hospitalization
Time Frame: Up to 36 months
|
Up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of treatment exposure
Time Frame: Up to 36 months
|
Up to 36 months
|
Number of subjects requiring titration of dose
Time Frame: Up to 36 months
|
Up to 36 months
|
Change of reticulocyte count from baseline of this study
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of red blood cell count from baseline of this study
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of hematocrit from baseline of this study
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of central laboratory hemoglobin level from baseline of this study
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Time within hemoglobin target range (10.0 to 12.0 g/dL)
Time Frame: Up to 36 months
|
Up to 36 months
|
Responders in Hb levels
Time Frame: Up to 36 months
|
Up to 36 months
|
Number of subjects meeting specific Hb criteria
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Number of subjects with Hb values >13 g/dL or having excessive Hb increase
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Number of participants with non-serious adverse events
Time Frame: Up to 36 months
|
Up to 36 months
|
Change in heart rate (HR)
Time Frame: Up to 36 months
|
Up to 36 months
|
Change in blood pressure (BP)
Time Frame: Up to 36 months
|
Up to 36 months
|
Laboratory abnormalities
Time Frame: Up to 36 months
|
Up to 36 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of reticulocyte count from baseline of study 15141 or 15261
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of red blood cell count from baseline of study 15141 or 15261
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of hematocrit from baseline of study 15141 or 15261
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Change of central laboratory hemoglobin level from baseline of study 15141 or 15261
Time Frame: Baseline up to 36 months
|
Baseline up to 36 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15653
- 2013-001190-24 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency, Chronic
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
University of PennsylvaniaTeleflex; Arrow InternationalCompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal InsufficiencyUnited States
-
Hospices Civils de LyonCompletedChronic Renal Insufficiency | Cardiac TransplantationFrance
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
Southern Medical University, ChinaTerminatedChronic Kidney Failure
-
Centre Hospitalier Universitaire de NiceTerminatedAged | Chronic Renal Insufficiency | Chronic Kidney FailureFrance
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
Clinical Trials on Molidustat (BAY85-3934)
-
BayerCompleted
-
BayerRecruiting
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaJapan
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaJapan
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaUnited States, Japan
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaJapan
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaJapan
-
BayerCompletedRenal Insufficiency, Chronic | AnemiaJapan
-
BayerCompleted